Targeted Radionuclide Tumor Therapy Biological Aspects
The last three decades have provided opportunities to explore the potential of treating malignant diseases with antibodies or other targeting molecules labelled with nuclides. The expanding array of new targeting molecules (recombinant antibodies or peptides) may increase the therapeutic efficacy. T...
| Other Authors: | , , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Dordrecht
Springer Netherlands
2008, 2008
|
| Edition: | 1st ed. 2008 |
| Subjects: | |
| Online Access: | |
| Collection: | Springer eBooks 2005- - Collection details see MPG.ReNa |
Table of Contents:
- to Radionuclide Therapy
- Therapeutically Used Targeted Antigens in Radioimmunotherapy
- EGFR-Family Expression and Implications for Targeted Radionuclide Therapy
- Targeting Tumours with Radiolabeled Antibodies
- Antibody Fragments Produced by Recombinant and Proteolytic Methods
- Novel Alternative Scaffolds and Their Potential Use for Tumor Targeted Radionuclide Therapy
- Peptides for Radionuclide Therapy
- Choice of Radionuclides and Radiolabelling Techniques
- High-LET-Emitting Radionuclides for Cancer Therapy
- Targeted High-LET Therapy of Bone Metastases
- The Auger Effect in Molecular Targeting Therapy
- Radiation Induced Cell Deaths
- Radiation Induced DNA-Damage/Repair and Associated Signaling Pathways
- Radiation Induced DNA Damage Checkpoints
- Cancer Stem Cells and Radiation
- Effects of Low Dose-Rate Radiation on Cellular Survival
- Bystander Effects and Radionuclide Therapy
- Enhancing the Efficiency of Targeted Radionuclide Therapy
- Low Dose Hyper-Radiosensitivity: A Historical Perspective
- Clinical Radionuclide Therapy
- Developmental Trends in Targeted Radionuclide Therapy: Biological Aspects